Syndax Pharmaceuticals, Inc.
Selection of patients for combination therapy

Last updated:

Abstract:

Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.

Status:
Grant
Type:

Utility

Filling date:

2 Sep 2016

Issue date:

26 Jul 2022